Serum atherogenicity

Serum atherogenicity describes the ability of a person's blood serum to promote cholesterol accumulation in target cells—particularly arterial wall smooth muscle cells—which is thought to reflect the risk for atherosclerosis[1][3]. This property is largely determined by the composition and modification status of lipoproteins in serum (such as oxidized LDL, small dense LDL, and apolipoprotein content), as well as some non-lipid factors[1][3][7]. The atherogenicity of serum can be quantified in laboratory settings by measuring its effect on cholesterol accumulation in cultured vascular cells, but it is not a discrete molecular entity and thus is not a conventional drug target like an enzyme or receptor[1][3]. Various drugs can reduce serum atherogenicity (notably statins and certain antihypertensives) or increase it (some beta-blockers, phenothiazines, and oral hypoglycemics), but these effects are mediated through changes in lipoprotein metabolism and other systemic properties—not by direct interaction with a single molecular target[3][7]. Biomarkers associated with serum atherogenicity include the apolipoprotein B/apolipoprotein A-I ratio, the atherogenic index of plasma, and the presence of small dense LDL[1][5][7]. The concept is relevant clinically in terms of cardiovascular risk assessment rather than as a druggable molecular entity[1][3]. Summary of key technical points: - "Serum atherogenicity" is not a single molecular entity and is not a canonical therapeutic target[1][3]. - It is a property relating to serum's ability to induce atherogenic processes—mainly via modified LDL and possibly non-lipid factors[1][3]. - Best interpreted as a functional biomarker or phenotype, not as a target for direct molecular intervention[1][3][7]. - Laboratory and some clinical studies assess drugs' effects on serum atherogenicity, but this is indirect and not equivalent to targeting a specific molecule or receptor[3][1].

Other names

Blood serum atherogenicitySerum atherogenic potentialAtherogenic serum

Reduction of serum atherogenicity by lowering serum LDL and/or modifying lipoprotein oxidation and metabolism; Some drugs affect endothelial function or lipid absorption